340 related articles for article (PubMed ID: 26903362)
1. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.
Pass HI; Goparaju C; Espin-Garcia O; Donington J; Carbone M; Patel D; Chen Z; Feld R; Cho J; Gadgeel S; Wozniak A; Chachoua A; Leighl N; Tsao MS; de Perrot M; Xu W; Liu G
J Thorac Oncol; 2016 Jun; 11(6):900-9. PubMed ID: 26903362
[TBL] [Abstract][Full Text] [Related]
2. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R
Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Gillezeau CN; van Gerwen M; Ramos J; Liu B; Flores R; Taioli E
Carcinogenesis; 2019 Nov; 40(11):1320-1331. PubMed ID: 31169881
[TBL] [Abstract][Full Text] [Related]
4. External validation of prognostic indices for overall survival of malignant pleural mesothelioma.
Kataoka Y; Yamamoto Y; Otsuki T; Kaku S; Maehashi-Wada N; Fukuma S; Hirabayashi M; Nakano T; Fukuhara S
Lung Cancer; 2017 Nov; 113():88-92. PubMed ID: 29110856
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma.
Gill RR; Yeap BY; Bueno R; Richards WG
J Natl Cancer Inst; 2018 Mar; 110(3):258-264. PubMed ID: 29931180
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.
Otoshi T; Kataoka Y; Kaku S; Iki R; Hirabayashi M
In Vivo; 2018; 32(2):445-450. PubMed ID: 29475935
[TBL] [Abstract][Full Text] [Related]
7. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
[TBL] [Abstract][Full Text] [Related]
8. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.
Hoda MA; Dong Y; Rozsas A; Klikovits T; Laszlo V; Ghanim B; Stockhammer P; Ozsvar J; Jakopovic M; Samarzija M; Brcic L; Bendek M; Szirtes I; Reid G; Kirschner MB; Kao SC; Opitz I; Weder W; Frauenfelder T; Nguyen-Kim TD; Aigner C; Klepetko W; van Zandwijk N; Berger W; Dome B; Grusch M; Hegedus B
Eur J Cancer; 2016 Aug; 63():64-73. PubMed ID: 27288871
[TBL] [Abstract][Full Text] [Related]
9. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
[TBL] [Abstract][Full Text] [Related]
10. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
11. Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis.
Smeele P; d'Almeida SM; Meiller C; Chéné AL; Liddell C; Cellerin L; Montagne F; Deshayes S; Benziane S; Copin MC; Hofman P; Le Pimpec-Barthes F; Porte H; Scherpereel A; Grégoire M; Jean D; Blanquart C
Mol Cancer; 2018 Oct; 17(1):148. PubMed ID: 30309369
[TBL] [Abstract][Full Text] [Related]
12. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
[TBL] [Abstract][Full Text] [Related]
13. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
[TBL] [Abstract][Full Text] [Related]
14. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
15. Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome.
Lacerenza S; Ciregia F; Giusti L; Bonotti A; Greco V; Giannaccini G; D'Antongiovanni V; Fallahi P; Pieroni L; Cristaudo A; Lucacchini A; Mazzoni MR; Foddis R
Cancer Genomics Proteomics; 2020; 17(3):225-236. PubMed ID: 32345664
[TBL] [Abstract][Full Text] [Related]
16. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
[TBL] [Abstract][Full Text] [Related]
17. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
Schneider MA; Muley T; Kahn NC; Warth A; Thomas M; Herth FJ; Dienemann H; Meister M
Oncotarget; 2016 Nov; 7(44):71285-71297. PubMed ID: 27713145
[TBL] [Abstract][Full Text] [Related]
18. Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment.
Creaney J; Robinson BWS
Chest; 2017 Jul; 152(1):143-149. PubMed ID: 28007619
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.
Yamagishi T; Fujimoto N; Nishi H; Miyamoto Y; Hara N; Asano M; Fuchimoto Y; Wada S; Kitamura K; Ozaki S; Kishimoto T
Lung Cancer; 2015 Oct; 90(1):111-7. PubMed ID: 26259877
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of soluble CD26 in malignant pleural mesothelioma.
Fujimoto N; Ohnuma K; Aoe K; Hosono O; Yamada T; Kishimoto T; Morimoto C
PLoS One; 2014; 9(12):e115647. PubMed ID: 25526639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]